Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not ach...
Saved in:
Main Authors: | María Julia Lamberti (Author), Annunziata Nigro (Author), Fátima María Mentucci (Author), Natalia Belén Rumie Vittar (Author), Vincenzo Casolaro (Author), Jessica Dal Col (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis
by: Zhong-Xiang Xie, et al.
Published: (2015) -
Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review
by: Jiaqi Zhai, et al.
Published: (2023) -
A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma
by: Ye-Bin Pang, et al.
Published: (2019) -
Exposure to Low-Dose Radiation Enhanced the Antitumor Effect of a Dendritic Cell Vaccine
by: Sinian Wang, et al.
Published: (2019) -
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
by: Michel Siegel, et al.
Published: (2022)